Nurix Therapeutics/$NRIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nurix Therapeutics
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Ticker
$NRIX
Sector
Primary listing
Employees
317
Headquarters
Website
NRIX Metrics
BasicAdvanced
$2.4bn
-
-$3.41
1.80
-
Price and volume
Market cap
$2.4bn
Beta
1.8
52-week high
$25.09
52-week low
$8.20
Average daily volume
1.8m
Financial strength
Current ratio
6.338
Quick ratio
6.185
Long term debt to equity
13.641
Total debt to equity
14.441
Profitability
EBITDA (TTM)
-353.18
Gross margin (TTM)
-827.31%
Net profit margin (TTM)
-928.44%
Operating margin (TTM)
-982.37%
Effective tax rate (TTM)
0.08%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-40.06%
Return on equity (TTM)
-80.30%
Valuation
Price to revenue (TTM)
63.19
Price to book
5.98
Price to tangible book (TTM)
5.98
Price to free cash flow (TTM)
-7.629
Free cash flow yield (TTM)
-13.11%
Free cash flow per share (TTM)
-3.042
Growth
Revenue change (TTM)
-58.40%
Earnings per share change (TTM)
31.02%
3-year revenue growth (CAGR)
-15.50%
3-year earnings per share growth (CAGR)
4.89%
What the Analysts think about NRIX
Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.
NRIX Financial Performance
Revenues and expenses
NRIX Earnings Performance
Company profitability
NRIX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.